Explore the vast range of titles available.

Background Meat-products are considered an enriched media for mycotoxins. This study aimed to investigate the prevalence of toxigenic Aspergillus species in processed meat samples, HPLC-quantitative measurement of aflatoxin B 1 and ochratoxin A residues, and molecular sequencing of aflR1 and pks genes. One hundred and twenty processed beef meat specimens (basterma, sausage, and minced meat; n  = 40 for each) were collected from Ismailia Province, Egypt. Samples were prepared for total mold count, isolation, and identification of Aspergillus species. All samples were analyzed for the production of both Aflatoxin B 1 and Ochratoxin A mycotoxins by HPLC. Molecular identification of Aspergillus flavus and Aspergillus ochraceus was performed using PCR amplification of the internal transcribed spacer (ITS) region; furthermore, the aflR1 and pks genes were sequenced. Results The total mold count obtained from sausage samples was the highest one, followed by minced meat samples. The prevalence of A. flavus was (15%), (7.5%), and (10%), while the prevalence of A. ochraceus was (2.5%), (10%), and (0%) in the examined basterma, sausage, and minced meat samples, respectively. Using PCR, the ITS region was successfully amplified in all the tested A. flavus and A. ochraceus strains. Aflatoxin B 1 was detected in six basterma samples (15%). Moreover, the ochratoxin A was detected only in four sausage samples (10%). The aflR1 and pks genes were amplified and sequenced successfully and deposited in the GenBank with accession numbers MF694264 and MF694264, respectively. Conclusions To the best of our knowledge, this is the first report concerning the HPLC-Molecular-based approaches for the detection of aflatoxin B 1 and ochratoxin A in processed beef meat in Egypt. The production of aflatoxin B 1 and ochratoxin A in processed meat constitutes a public health threat. Aflatoxin B 1 is commonly associated with basterma samples. Moreover, ochratoxin A was detected frequently in sausage samples. The routine inspection of mycotoxins in processed meat products is essential to protect human consumers.

The development of therapies for rare diseases (RDs) continues to face persistent challenges, including small and geographically dispersed patient populations, pronounced clinical heterogeneity, and the absence of standardized outcome measures. Basket trials—master protocol studies evaluating a single therapeutic intervention across multiple diseases linked by shared molecular or clinical characteristics—offer a promising solution to these constraints. This systematic review identified 36 basket trials targeting RDs through comprehensive searches of clinical trial registries, academic databases, and grey literature. The majority (75%) focused on rare oncological indications, with only nine trials addressing non-oncological RDs. These non-oncological studies were highly heterogeneous, spread across 25 distinct conditions without overlap, and faced persistent challenges such as the lack of validated biomarkers and standardized endpoints. Most studies (81%) were Phase II trials, highlighting the exploratory role of basket designs in early-stage development. Trial designs were predominantly non-randomized and open-label (86%), reflecting the practical limitations of implementing rigorous methodologies in small, heterogeneous populations. The average trial duration was 6.5 years, and recruitment was logistically demanding, with trials involving a mean of 56 sites and, in some cases, over 1,000 centers. While basket trials show clear potential to accelerate therapeutic innovation in RDs, their application remains limited beyond oncology. Methodological constraints—such as inconsistent endpoints, limited randomization, and underpowered subgroup analyses—continue to restrict their broader use. Enhancing the utility of basket trials will require greater regulatory flexibility, wider adoption of adaptive and Bayesian designs, integration of real-world evidence, and stronger engagement with patients and advocacy groups. This review underscores both the opportunities and limitations of basket trials in RDs and provides a roadmap for realizing their potential, calling for concerted efforts from regulators, researchers, and patient advocates to expand their application and impact across the RDs spectrum.

Heterogeneous wireless sensor networks (HWSNs), comprising super nodes and normal sensors, offer a promising solution for monitoring diverse environments. However, their deployment is constrained by the limited battery life of sensors. To address this issue, clustering and routing techniques have been employed to conserve energy. Nevertheless, existing approaches often struggle with suboptimal energy distribution and weak network coverage. Additionally, they mostly failed to exploit other energy saving techniques such as sleep scheduling. This paper proposes a novel genetic algorithm (GA)-based approach to optimize sleep scheduling, routing, and clustering in HWSNs. The method comprises two phases, namely join sleep scheduling and tree construction, and clustering of normal nodes. Inspired by the concept of unequal clustering, the HWSN is split into some rings in the first phase, and the number of awake super nodes in each ring keeps the same. This approach addresses the challenges of balancing energy consumption and network lifetime. Furthermore, including network coverage and energy-related criteria in the proposed GA yields long-lasting network operation. Through rigorous simulations, we demonstrate that, on average, our algorithm reduces energy consumption and improves network coverage by 23% and 21.9%, respectively, and extends network lifetime by 501 rounds, compared to the state-of-the-art methods.

Previous studies suggest glial and neuronal changes may trigger synaptic dysfunction in Alzheimer’s disease (AD), but the link between their markers and synaptic abnormalities in the living brain remains unclear. We investigated the association between glial reactivity and synaptic dysfunction biomarkers in cerebrospinal fluid (CSF) from 478 individuals in cognitively unimpaired (CU) and cognitively impaired (CI) individuals. We measured amyloid-β (Aβ), phosphorylated tau (pTau181), astrocyte reactivity (GFAP), microglial activation (sTREM2), and synaptic markers (GAP43, neurogranin). CSF GFAP levels were associated with presynaptic and postsynaptic dysfunction, independent of cognitive status or Aβ presence. CSF sTREM2 levels were related to presynaptic markers in cognitively unimpaired and impaired Aβ+ individuals, and to postsynaptic markers in cognitively impaired Aβ+ individuals. Notably, CSF pTau mediated the relationships between GFAP or sTREM2 and synaptic dysfunction. Our findings, validated in two independent cohorts (TRIAD and ADNI), reveal a distinct pattern of glial contribution to synaptic degeneration. This study shows that glial reactivity is linked to synaptic dysfunction in aging and Alzheimer’s disease, with tau pathology mediating these effects–highlighting the potential of synaptic biomarkers track disease progression.

IntroductionMorbidity from an emergency laparotomy (EmLap) is difficult to define and poorly understood. Morbidity is a holistic concept, reliant upon an interplay of bio-psychosocial outcomes that evolve long after discharge. To date, no previous study has explored the psychosocial outcomes following EmLap as a collective, nor their change over time. This study aims to describe the holistic morbidity following EmLap within the first year following surgery.Methods and analysisThis is a multicentre, mixed-methods prospective 12-month cohort study with two participant populations: patient participants and family caregivers (FCGs). A target of 160 adult patients who undergo EmLap and can give informed consent will be included in the patient participant group. Patient participants will be asked to complete three patient surveys, incorporating validated patient-reported outcome measures (PROMs) to assess bio-psychosocial outcomes (EuroQol five-dimension five-level (EQ5D-5L), Gastrointestinal Quality Life Index-36, Patient Health Questionnaire-9, Generalised Anxiety Disorder 7, International Trauma Questionnaire, Caregiver Interaction Scale and Fatigue Severity Scale) in the 12 months following surgery. A subgroup of 15 patient participants will be asked to take part in two semistructured interviews at 6 and 12 months. A target of 15 associated family caregivers will be included in the FCG group. FCGs will be asked to take part in a semi-structured interview at 6 months to assess the EmLap impact on the wider support network. The primary outcome will be a change in quality of life (EQ5D-5L) at 12 months. Secondary outcomes will be changes in bio-psychosocial status at 3 and 12 months. Qualitative analysis will allow contextualisation of PROMS and further explore themes of EmLap morbidity. It is anticipated that the results of this study will help inform and develop standards of aftercare for future EmLap patients.Ethics and disseminationThis study has received ethical approval (Wales REC7;12/WA/0297) and will be undertaken in accordance with the principles of Good Clinical Practice. We intend to disseminate study results in peer-reviewed journals and medical conferences, as well as a lay report to study participants.Trial registration numberClinical Trials.gov NCT05281627.

The use of phase change materials (PCMs) has become an increasingly common way to reduce a building’s energy usage when added to the building envelope. This developing technology has demonstrated improvements in thermal comfort and energy efficiency, making it a viable building energy solution. The current study intends to provide a comprehensive review of the published studies on the utilization of PCMs in various constructions of energy-efficient roofs, walls, and ceilings. The research question holds massive potential to unlock pioneering solutions for maximizing the usefulness of PCMs in reducing cooling demands, especially in challenging high-temperature environments. Several issues with PCMs have been revealed, the most significant of which is their reduced effectiveness during the day due to high summer temperatures, preventing them from crystallizing at night. However, this review investigates how PCMs can delay the peak temperature time, reducing the number of hours during which the indoor temperature exceeds the thermal comfort range. Additionally, the utilization of PCMs can improve the building’s energy efficiency by mitigating the need for cooling systems during peak hours. Thus, selecting the right PCM for high temperatures is both critical and challenging. Insulation density, specific heat, and thermal conductivity all play a role in heat transfer under extreme conditions. This study introduces several quantification techniques and paves the way for future advancements to accommodate practical and technical solutions related to PCM usage in building materials.

The study of neuroarchitecture is concerned with the significant effects of architecture on human behavior, emotions and thought processes. This review explores the intricate relationship between the brain and perceived environments, focusing on the roles of the anterior cingulate cortex (ACC) and parahippocampal place area (PPA) in processing architectural stimuli. It highlights the importance of mirror neurons in generating empathetic responses to our surroundings and discusses how architectural elements like lighting, color, and space layout significantly impact emotional and cognitive experiences. The review also presents insights into the concept of cognitive maps and spatial navigation, emphasizing the role of architecture in facilitating wayfinding and orientation. Additionally, it addresses how neuroarchitecture can be applied to enhance learning and healing environments, drawing upon principles from the Reggio Emilia approach and considerations for designing spaces for the elderly and those with cognitive impairments. Overall, this review offers a neuroscientific basis for understanding how human cognition, emotions, spatial navigation, and well-being are influenced by architectural design.

Cerebrospinal fluid (CSF) total tau (t-tau) is considered a biomarker of neuronal degeneration alongside brain atrophy and fluid neurofilament light chain protein (NfL) in biomarker models of Alzheimer’s disease (AD). However, previous studies show that CSF t-tau correlates strongly with synaptic dysfunction/degeneration biomarkers like neurogranin (Ng) and synaptosomal-associated protein 25 (SNAP25). Here, we compare the association between CSF t-tau and synaptic degeneration and axonal/neuronal degeneration biomarkers in cognitively unimpaired and impaired groups from two independent cohorts. We observe a stronger correlation between CSF t-tau and synaptic biomarkers than neurodegeneration biomarkers in both groups. Synaptic biomarkers explain a greater proportion of variance in CSF t-tau levels compared to neurodegeneration biomarkers. Notably, CSF t-tau levels are elevated in individuals with abnormalities only in synaptic biomarkers, but not in individuals with abnormalities only in neurodegeneration biomarkers. Our findings suggest that CSF t-tau is a closer proxy for synaptic degeneration than for axonal/neuronal degeneration. CSF total tau (t-tau), often used as a marker of neuronal damage, is more strongly linked to synaptic degeneration. Here, the authors show that t-tau better reflects synaptic dysfunction than axonal or neuronal loss in Alzheimer’s disease.

Background This study aimed to investigate the safety and efficacy of the Yamane technique (flanged intrascleral haptic fixation with double-needle technique /FIHFT) for three-piece intraocular lens (IOL) implantation in Egyptian patients diagnosed with Marfan syndrome (MFS) presented with subluxated lenses (ectopia lentis, EL). Methods This was a retrospective evaluation of thirty-three patients who were diagnosed with MFS and had subluxated lenses in a total of forty eyes. Seven of these patients had bilateral subluxation. Lensectomy or phacoemulsification was performed with limited anterior vitrectomy, followed by IOL implantation using the FIHFT method. Data was collected from medical records, including preoperative and postoperative corrected distant visual acuity (CDVA) using logarithm of the minimal angle of resolution (log MAR), preoperative and postoperative refractions, intraoperative and postoperative complications, and follow-up periods. Results The mean age of patients in the study was 30.79 years, with a mean follow-up of 23.9 months. Post-surgery, the refractive sphere decreased significantly from -9.1 ± 1.4 diopter (D) to -1.4 ± 0.7 D, and cylinder measurements dropped from -4.5 ± 0.8 D to -1.4 ± 0.6 D. The spherical equivalent (SEQ) also declined from -11.4 ± 1.5 D to -2.1 ± 0.8 D. The CDVA improved from 0.80 ± 0.32 to 0.18 ± 0.10 log MAR ( P  < 0.001). No intraoperative complications were identified. Postoperative complications included IOL decentration (12.5%), vitreous hemorrhage (7.5%), IOL slippage (5%), IOL tilt (5%), and retinal detachment (RD) (5%). Further surgical procedures were necessary for only four cases (10%), all of which had positive outcomes. IOL tilting and slippage occurring at average ages of 18 and 19 years, respectively. No other complications, such as hypotony, elevated intraocular pressure (IOP), corneal edema, iritis, IOL dislocation, cystoid macular edema (CME) or endophthalmitis, were reported. Conclusions The Yamane technique has proven effective and safe for treating subluxated lenses in Egyptian patients with Marfan Syndrome, resulting in improved visual acuity with minimal complications, mostly minor and manageable. Comprehensive fundus examinations before and after surgery are essential for promptly identifying retinal breaks and reducing the risk of retinal detachment. IOL tilting and slippage are more common in younger patients.